Initial results from a phase I, open-label, dose escalation study of the oral BRAF inhibitor LGX818 in patients with BRAF V600 mutant advanced or metastatic melanoma

被引：0
|
作者：
Dummer, Reinhard
Robert, Caroline
Nyakas, Marta
McArthur, Grant A.
Kudchadkar, Ragini Reiney
Gomez-Roca, Carlos
Sullivan, Ryan J.
Flaherty, Keith
Murer, Carla
Michel, Daniela
Tang, Zhongwen
De Parseval, Laure A.
Delord, Jean-Pierre
机构：
[1] Univ Zurich Hosp, CH-8091 Zurich, Switzerland
[2] Inst Gustave Roussy, Villejuif, France
[3] Oslo Univ Hosp, Oslo, Norway
[4] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[5] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[6] Inst Claudius Regaud, Toulouse, France
[7] Massachusetts Gen Hosp, Boston, MA 02114 USA
[8] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA
[9] Novartis Pharma AG, Basel, Switzerland
[10] Novartis Pharmaceut, E Hanover, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9028
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Tunlametinib (HL-085) plus vemurafenib in patients with advanced BRAF V600-mutant solid tumors: an open-label, single-arm, multicenter, phase I study
    Shi, Yuankai
    Han, Xiaohong
    Zhao, Qian
    Zheng, Yulong
    Chen, Jianhua
    Yu, Xinmin
    Fang, Jian
    Liu, Yutao
    Huang, Dingzhi
    Liu, Tianshu
    Shen, Hong
    Luo, Suxia
    Yu, Hongsheng
    Cao, Yu
    Zhang, Xi
    Hu, Pei
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2024, 13 (01)
  • [22] An open-label phase 2a study of combination dabrafenib (D) and trametinib (T) in Asian patients (pts) with advanced BRAF V600-mutant acral lentiginous melanoma (ALM) or cutaneous melanoma (CM)
    Guo, J.
    Chang, W-C.
    Dechaphunkul, A.
    Fan, Y.
    Kim, T. M.
    Lin, C-C.
    Maneechavakajorn, J.
    Shin, S. J.
    Song, X.
    Cheng, S-T.
    Thongprasert, S.
    Wong, C. S.
    Wu, D.
    Zhang, X.
    Bettinger, S.
    Zhang, P.
    Mookerjee, B.
    ANNALS OF ONCOLOGY, 2016, 27
  • [23] BRIM-P: A phase I, open-label, multicenter, dose-escalation study of vemurafenib in pediatric patients with surgically incurable, BRAF mutation-positive melanoma
    Chisholm, Julia C.
    Suvada, Jozef
    Dunkel, Ira J.
    Casanova, Michela
    Zhang, Weijiang
    Ritchie, Natasha
    Choi, YounJeong
    Park, Jane
    Das Thakur, Meghna
    Simko, Stephen
    Tam, Nga Wan Rachel
    Ferrari, Andrea
    PEDIATRIC BLOOD & CANCER, 2018, 65 (05)
  • [24] Phase I, open-label study of pasireotide in patients with BRAF-wild type and NRAS-wild type, unresectable and/or metastatic melanoma
    Dummer, Reinhard
    Michielin, Olivier
    Nageli, Mirjam Chantal
    Goldinger, Simone M.
    Campigotto, Federico
    Kriemler-Krahn, Ulrike
    Schmid, Herbert
    Pedroncelli, Alberto
    Micaletto, Sara
    Schadendorf, Dirk
    ESMO OPEN, 2018, 3 (05)
  • [25] First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors
    Rodrigo Dienstmann
    Ulrik Lassen
    Jonathan Cebon
    Jayesh Desai
    Michael P. Brown
    Stefan Evers
    Fei Su
    Weijiang Zhang
    Frederic Boisserie
    Brian Lestini
    Kathleen Schostack
    Valerie Meresse
    Josep Tabernero
    Targeted Oncology, 2016, 11 : 149 - 156
  • [26] Triplet therapy with pembrolizumab (PEM), encorafenib (ENC) and binimetinib (BIN) in advanced, BRAF V600 mutant melanoma: Final results from the dose-finding phase I part of the IMMU-Target trial.
    Zimmer, Lisa
    Krackhardt, Angela
    Schultz, Erwin S.
    Goeppner, Daniela
    Assaf, Chalid
    Trebing, Dietrich
    Livingstone, Elisabeth
    Schadendorf, Dirk
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [27] First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors
    Dienstmann, Rodrigo
    Lassen, Ulrik
    Cebon, Jonathan
    Desai, Jayesh
    Brown, Michael P.
    Evers, Stefan
    Su, Fei
    Zhang, Weijiang
    Boisserie, Frederic
    Lestini, Brian
    Schostack, Kathleen
    Meresse, Valerie
    Tabernero, Josep
    TARGETED ONCOLOGY, 2016, 11 (02) : 149 - 156
  • [28] CA184-161: A phase I/II trial of vemurafenib and ipilimumab in patients with BRAF V600 mutation-positive metastatic melanoma.
    Ribas, Antoni
    Hodi, F. Stephen
    Kurland, John F.
    Shahabi, Vafa
    Francis, Stephen
    Konto, Cyril
    Joe, Andrew K.
    Lainas, Ioannis
    Wolchok, Jedd D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [29] BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma.
    Ribas, A.
    Kim, K. B.
    Schuchter, L. M.
    Gonzalez, R.
    Pavlick, A. C.
    Weber, J. S.
    McArthur, G. A.
    Hutson, T. E.
    Flaherty, K. T.
    Moschos, S. J.
    Lawrence, D. P.
    Hersey, P.
    Kefford, R. F.
    Chmielowski, B.
    Puzanov, I.
    Li, J.
    Nolop, K. B.
    Lee, R. J.
    Joe, A. K.
    Sosman, J. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [30] Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
    Long, Georgina V.
    Trefzer, Uwe
    Davies, Michael A.
    Kefford, Richard F.
    Ascierto, Paolo A.
    Chapman, Paul B.
    Puzanov, Igor
    Hauschild, Axel
    Robert, Caroline
    Algazi, Alain
    Mortier, Laurent
    Tawbi, Hussein
    Wilhelm, Tabea
    Zimmer, Lisa
    Switzky, Julie
    Swann, Suzanne
    Martin, Anne-Marie
    Guckert, Mary
    Goodman, Vicki
    Streit, Michael
    Kirkwood, John M.
    Schadendorf, Dirk
    LANCET ONCOLOGY, 2012, 13 (11) : 1087 - 1095
12345